Curatis Holding AG (CHIX:CURNZ) EPS (Basic) : CHF-163.76 (TTM As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Curatis Holding AG EPS (Basic)?

Curatis Holding AG's basic earnings per share (Basic EPS) for the six months ended in Jun. 2024 was CHF-0.88. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2024 was CHF-163.76.

Curatis Holding AG's EPS (Diluted) for the six months ended in Jun. 2024 was CHF-0.88. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was CHF-163.76.

Curatis Holding AG's EPS without NRI for the six months ended in Jun. 2024 was CHF-0.88. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was -6.25.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Curatis Holding AG EPS (Basic) Historical Data

The historical data trend for Curatis Holding AG's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curatis Holding AG EPS (Basic) Chart

Curatis Holding AG Annual Data

Trend

Dec21

Dec22

Dec23

EPS (Basic)

-3.90

-221.63

-176.38

Curatis Holding AG Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EPS (Basic)	Get a 7-Day Free Trial			-3.39	-134.19	-7.24	-162.88	-0.88

Curatis Holding AG EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Curatis Holding AG's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-49.38	-	0)	/	0.280
	=	-176.36

Curatis Holding AG's Basic EPS for the quarter that ended in Jun. 2024 is calculated as

Basic EPS (Q: Jun. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-3.869	-	0)	/	4.384
	=	-0.88

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-163.76

Curatis Holding AG (CHIX:CURNz) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Curatis Holding AG EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Curatis Holding AG's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Curatis Holding AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curatis Holding AG (CHIX:CURNz) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

26U:Germany CURN:Switzerland

Address

Weierweg 7, Liestal, CHE, CH-4410

Website

https://www.curatis.com

Curatis Holding AG is a specialty pharmaceutical company based in Switzerland. It focus on the acquisition, development and commercialisation of medicines for the prevention, diagnosis and treatment of rare and specialty care diseases. Curatis is engaged in two business areas: Distribution business for orphan disease and specialty care medicines and Development business for orphan and specialty care disease medicines. Its product include Aggrastat (Tirofiban), AmbiFul (Fulvestrant), Brinavess (Vernakalant), Coldistop, Cuprior (Trientin), Cyanokit (Hydroxocobalamin), etc.

Curatis Holding AG Headlines

No Headlines